• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Sexually Transmitted Infections >Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study.
【24h】

Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study.

机译：扎鲁司特用于严重复发性阴道阴道念珠菌病：一项开放标签的先导研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Recurrent vulvovaginal candidiasis (VVC) has been linked to allergic disease, particularly allergic rhinitis. OBJECTIVE: A pilot study to assess the possible use of the leukotriene receptor antagonist zafirlukast as a treatment for recurrent VVC. METHODS: 20 women with six or more symptomatic attacks of VVC in the past year (at least four proved microbiologically). Clinical atopy determined by the International Study for Asthma and Allergies in Childhood (ISAAC) questionnaire assessed blindly. Monitoring by daily symptom diary and self taken vaginal swabs. Treatment with zafirlukast 20 mg twice daily for 24 weeks or until three microbiologically confirmed episodes of VVC. Response assessed by daily symptom diary and self taken vaginal swabs. Subjective response scales for improvement, side effects, and change in other allergic disease completed when stopping treatment. Semistructured telephone interview 1 year after stopping medication. RESULTS: 14 patients (70%) reported a subjective response on the improvement response scale. Six (30%) showed a complete response with no further symptomatic attacks of VVC or negative swabs when symptomatic. Seven (37%) remained symptom free 18 months after entering the study-that is, 12 months after stopping therapy. 11 (58%) remained symptom free for at least 3 months after stopping therapy. This does not include one patient who remained symptom free but continued on zafirlukast because of an improvement in her asthma. There was no clear relation between response and atopic status. Six of nine atopic subjective responders reported improvements in other allergic symptoms. Side effects were minimal; one seemed clearly attributable to the drug. CONCLUSION: Zafirlukast offers a potential new treatment for recurrent VVC that requires confirmation in controlled studies.
机译：背景：复发性阴道阴道念珠菌病（VVC）与过敏性疾病，尤其是过敏性鼻炎有关。目的：一项初步研究评估白三烯受体拮抗剂扎鲁司特用于复发性VVC的可能应用。方法：在过去的一年中，有20名女性出现了6例或更多的VVC症状发作（至少4例经微生物学证实）。由国际儿童哮喘和过敏研究（ISAAC）调查表确定的临床特应性进行了盲目评估。通过每日症状日记和自行服用的阴道拭子进行监测。每天两次用扎鲁司特20 mg治疗，持续24周，或直到3次经微生物学证实的VVC发作。通过每日症状日记和自带阴道拭子评估反应。当停止治疗时，主观反应量表可用于改善，副作用和其他变态反应性疾病的改变。停止用药1年后进行的半结构式电话采访。结果：14名患者（70％）报告了主观反应，改善反应量表。六名（30％）表现出完全的反应，有症状时无进一步的VVC症状发作或阴性拭子发作。进入研究18个月（即停止治疗12个月）后，有7例（37％）保持无症状。停止治疗后，至少11个月（58％）无症状。这不包括一名无症状但由于哮喘改善而继续接受扎鲁司特治疗的患者。反应与特应性状态之间没有明确的关系。九位特应性主观反应者中有六例报告了其他过敏症状的改善。副作用很小;似乎很明显归因于该药物。结论扎鲁司特提供了一种潜在的复发性VVC新治疗方法，需要在对照研究中加以证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号